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Introduction: In recent years, there has been growing concern about an increasing rate of
cardiovascular diseases in human immunodeﬁciency virus-infected patients, which could
be associated with side effects of highly active antiretroviral therapy. It is likely that the
metabolic  disorders related to anti-human immunodeﬁciency virus treatment will eventu-
ally  translate into a increased cardiovascular risk in patients submitted to such regimens.
Objective: To evaluate if human immunodeﬁciency virus-infected patients receiving highly
active antiretroviral therapy are at higher risk of cardiovascular diseases than human
immunodeﬁciency virus infected patients not receiving highly active antiretroviral therapy,
or  the general population.
Research  design and methods: We conducted a computer-based search in representative
databases,  and also performed manual tracking of citations in selected articles.
Result: The available evidence suggests an excess risk of cardiovascular events in human
immunodeﬁciency  virus-infected persons compared to non-human immunodeﬁciency
virus  infected individuals. The use of highly active antiretroviral therapy is associ-
ated  with increased levels of total cholesterol, triglycerides, low-density lipoprotein and
morphological  signs of cardiovascular diseases. Some evidence suggested that human
immunodeﬁciency  virus-infected individuals on highly active antiretroviral therapy regi-
mens  are at increased risk of dyslipidemia, ischemic heart disease, and myocardial
infarction,  particularly if the highly active antiretroviral therapy regimen contains a protease
inhibitor.
Conclusion:  Physicians must weigh the cardiovascular risk against potential beneﬁts when
prescribing  highly active antiretroviral therapy. Careful cardiac screening is warranted for
patients who are being evaluated for, or who are receiving highly active antiretroviral therapy
regimens,  particularly for those with known underlying cardiovascular risk factors. A better
understanding of the molecular mechanisms responsible for increased risk of cardiovascularmudiseases  in human imnew drugs that will reduc
patients  receiving highly 
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Table 1 – PICO.
Population HIV-infected adults
Intervention Antiretroviral therapy (when applicable)
Comparator HIV-infected adults without antiretroviral
therapy
General  population
Outcome Cardiovascular Disease or Cardiovascular
Risk  Factors692  b r a z j i n f e c t d 
Introduction
The widespread use of highly active antiretroviral ther-
apy  (HAART) – comprising protease inhibitors (PIs) and/or
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
combined with nucleoside reverse-transcriptase inhibitors
(NRTIs)  – has dramatically decreased the morbidity and mor-
tality  associated with human immunodeﬁciency virus (HIV)
infection  in the developed world.1,2
Since the introduction of HAART in 1995, a signiﬁcant
decrease in mortality was  observed in HIV-infected patients
associated with a marked reduction in the incidence of oppor-
tunistic  infections and certain kind of cancers.3,4 However,
current evidence suggests that patients on HAART are at
increased  risk of developing cardiovascular disease (CVD), and
recent  studies reported a higher prevalence of traditional risk
factors  for CVD in HIV-infected patients than in non-infected
controls, such as arterial hypertension, dyslipidemia, and dia-
betes mellitus. These abnormalities may  be associated with
the  use of certain antiretroviral drugs.5
HIV infection leads to a chronic systemic inﬂamma-
tory process, which is increasingly accepted as having an
important  role in the pathogenesis of atherosclerosis and
acute  cardiovascular events. HIV-infected patients have been
described  as presenting unique histological features of coro-
nary  artery disease, including a rapid progression of diffuse
circumferential arterial lesions with proliferation of smooth
muscle  cells, elastic ﬁbers, and endoluminal protrusions.6
HIV-infected patients with acute coronary syndrome tend
to  be younger, with lower high-density lipoprotein (HDL) lev-
els,  higher prevalence of smoking, and less angiographically
apparent coronary artery disease, when compared to non-
HIV  patients, which represents a different epidemiological
pattern. HIV-infected patients may  have concomitant tradi-
tional  risk factors for CVD such as smoking, hypertension,
and dyslipidemia, but the HIV and HAART may  interact with
these  factors and contribute to the increased incidence of
CVD.  The long-term beneﬁts of HAART are remarkable, but
the  associated complications make the overall management
of  HIV-infected patients more  complex and costly.7
Because of the dissemination of HIV infection and its
potential association with CVD, some authors have proposed
a  routine and systematic evaluation of HIV-infected adults
and  children, including medical history, cardiac examination
and  systematic echocardiographic monitoring, since asymp-
tomatic  cardiac disease and cardiac symptoms can often be
misled  by secondary effects of HIV infection.8
The aim of this review was  to evaluate if HIV-infected
patients receiving HAART are at higher risk of CVD in rela-
tion  to HIV-infected patients not receiving HAART and to the
general  population.
MethodsWe  performed a computer-based search, querying Ovid MED-
LINE  (1950 to July 2012), CINAHL (Cumulative Index to Nursing
and  Allied Health, 1982 to July 2012), EMBASE (1980 to July
2012),  and the Cochrane Central Register of Controlled TrialsType of study Randomized Clinical Trials (RTC) and
Observational Studies
for original research articles published in English, Span-
ish  and Portuguese. Medical Subject Headings (MeSH) were
used  as search terms when available, and keywords were
used  when appropriate. Terms for Anti-HIV Agents, HIV
Infections, Cardiovascular Diseases, and Cardiovascular Dis-
eases/complications were  combined with a variety of MeSH
terms  to delimit relevant study designs and populations.
The selected outcome measures were common clinical
cardiovascular outcomes (e.g. ischemic heart disease (IHD),
heart  failure (HF), cerebrovascular disease, acute coronary
syndrome, myocardial infarction (MI) and peripheral vascular
disease),  or established traditional risk factors for CVD (e.g.
hypertension and hypercholesterolemia).
One reviewer made the search and the initial selection
of  potentially relevant studies meeting the inclusion crite-
ria  and two independent reviewers selected articles that met
the  established inclusion and exclusion criteria. Studies were
assessed  for use of an appropriate source population, mea-
surement  methods of exposure and outcome, methods to deal
with design-speciﬁc issues such as bias and lost to follow-up,
use  of analytical methods and use of statistics for primary
analysis of effect. A manual tracking of citations in articles
selected  was  also performed.
The  structure of the search is shown in Table 1. Abstracts
and relevant full-text articles were reviewed by one researcher.
Results
Design  of  clinical  trials  and  subjects
The search strategy identiﬁed 205 titles, 159 of which were
excluded  because they did not match the source population,
outcome or study design did not address the research ques-
tion.  Of 46 potential articles, only 26 were  directly related to
the  main goal of this review, and two studies were  added after
manual  search. A total of 28 articles were included in the
review:  four randomized clinical trials and 24 observational
studies being 22 prospective cohorts and two case–control
studies.
Table 2 summarizes the main characteristics and results of
studies  included in this review.
Evidence from the included studies indicates that expo-
sure  to antiretroviral drugs is associated with an increased
rate  of CVD events. HIV infection decreases good cholesterol,
increases triglycerides (TG), total cholesterol (TC), and vas-
cular  inﬂammation.10,16–19,22,24,25,30 Traditional cardiovascular
risk (CVR) factors substantially contribute to the development
of  diastolic dysfunction (DD) in the HIV-infected patients.15
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Table 2 – Study characteristics and results.
Study Type of study Population-follow-up Drugs Results Outcomes
Coplan et al., 20039 Prospective cohort 10,986 HIV-patients which
7951  received PI therapy –
12  months
IDV, NFV, SQV
Ritonavir
RR  of MI were 1.69 (0.54, 7.48) in PI-containing
HAART  and 1.74 (0.5, 9.0) for patients with
NRTI-only regimens.
No difference in MI
incidence  between the PI
containing  or not
containing groups
Llibre et al., 200610 Prospective cohort 352 HIV-patients in use of 3
antiretroviral  drugs – 48
weeks
Substitution  of TDF by d4T Reduction  in TC (−17.5 mg/dL; p < 0.001), LDL-C
(−8.1 mg/dL; p < 0.001) and TG (−35 mg/dL;
p < 0.001) at 48 weeks of follow up.
TC reduction
HDL and LDL-C reduction
TG  reduction
Velenzuela et al.,
200711
Prospective cohort 276 patients:
168 – HAART and PI
108  – HAART – 4 months
NS  Low CVR but higher TC and TG in the
subpopulation of patients who received PI
Low  CVR; higher TC and TG
in  the subpopulation of
patients  who received PI
Brothers et al.,
200912
Prospective cohort HIV received ABC (n = 9502)
or not (n = 4672) – 24 week
ABC and NS MI were comparable among subjects exposed
n = 16 (0.168%); or not n = 11 (0.235%) to
ABC-containing therapy.
CAD and MI events were
similar  across ABC-exposed
and  non-ABC-exposed
groups
Worm et al., 201013 Prospective cohort 33,308 HIV-patients
(D:A:D Study) – >1 year
AZT,  ddI, ddC, d4T, 3TC,
ABC,  TDF, IDV, NFV, LPV,
SQV,  NVP, EFV
Recent  exposure to ABC or ddi was associated
with an increased risk of MI. Cumulative
exposure  to IDV and LPV was associated with an
increased risk of MI.
Increased risk of MI
associated  with IDV, LPV,
ddI,  ABC
Cahn et al., 201014 Prospective cohort 4010 HIV-patients receiving
HAART  for at least 1 month
–  2 years
NS The overall 10-year risk of CVD, as measured by
the FRF, was 10.4 (24.7). The FRF score increased
with duration of HAART.
80.2% of dyslipidemia
20.2%  of metabolic
syndrome
Obel et al., 201015 Prospective cohort 2952 HIV-patient ABC, AZT, d4T, ddI, 3TC RR  of MI hospitalization with ABC was 2.22 (95%
CI 1.31–3.76). The risk of MI increased after
initiation of ABC IRR adjusted for
confounders  = 2.00 (95% CI 1.10–3.64).
Saint-Martin et al.,
201016
Prospective cohort 33 ATV/r > 6 months
99 ATV/r naive controls – 18
months
ATV/R
Others
The  CIMT course signiﬁcantly decreased
(p = 0.018) in cases at 18 months.
CIMT signiﬁcantly
decreased (p = 0.018)
Ribaudo et al., 201117 Prospective cohort 1704 received ABC
3352  no ABC – 3.1 years
NS  6 years after ART initiation, 36 MI events were
observed in 17,404 person-years. No evidence of
an increased hazard of MI in subjects using ABC
vs. no ABC was seen (over a 1-year period:
p = 0.50; HR = 0.7 [95% CI, 0.2–2.4]).
No  evidence that initial ART
containing ABC increases
MI  risk over short-term and
long-term  periods
Durand et al., 201118 Prospective cohort 7053 HIV-positive patients
were  matched to 27,681
HIV-negative  patients
ABC
LPV
EFV
The  drugs that were associated with an
increased risk of AMI for any exposure were ABC
OR = 1.79, lopinavir OR = 1.98, ritonavir OR = 2.29
and EFZ OR = 1.83.
HIV+  were at higher risk of
AMI  than the general
population, and several
ARTs  were associated with
an  increased risk of AMI
694
 
b
 r
 a
 z
 j
 i
 n
 f
 e
 c
 t
 d
 i
 s
 .
 2
 0
 1
 3
;1
 7
(6
):691–700
Table 2 (Continued)
Study Type of study Population-follow-up Drugs Results Outcomes
Friis-Moller et al.,
200319
Prospective cohort 17,852 patients enrolled in
DAD  from nine of 11
participating  cohorts
PIs,  NNRTIs Increased prevalence of elevated TC among
subjects receiving an NNRTI but no PI OR = 1.79,
PI  but no NNRTI OR = 2.35, or NNRTI + PI OR = 5.48
compared to the prevalence among antiretroviral
therapy (ART)-naïve subjects.
CVD risk factors were
prevalent.  With the highest
prevalence  among patients
receiving  PI, NNRTI or both
of  these drug classes
Choi et al., 201121 Prospective cohort 10,931 HIV-infected patients
initiating antiretroviral
therapy  in the Veterans
Health  Administration from
1997  to 2007
ABC
TDF
123  cardiovascular events in 15,142 person-years
of <6 months ABC use and 90 in 22 551
person-years TDF use. Incidence of any CVD
event were higher in the setting of ABC use
compared with TDF use or other ART (13.4 vs. 9.4
per 1000 person-years p < 0.01.
Recent ABC exposure was
signiﬁcantly  associated
with  higher risk of
atherosclerotic vascular
events,  and recent TDF
exposure  was signiﬁcantly
associated  with HF
DAD Study Group,
200322
Prospective cohort 23,468 HIV-patients were
enrolled  from 11 previously
cohorts
PIs
NRTIs
The  incidence of MI increased with longer
exposure to combination antiretroviral therapy
(adjusted relative rate per year of exposure, 1.26
[95 percent conﬁdence interval, 1.12 to 1.41];
p < 0.001).
Combination  ART was
independently  associated
with  a 26% relative increase
in  MI per year of exposure
Masiá et al., 200723 Prospective cohort 245 consecutive
HIV-infected patients
during  a 2-month period
Naïve
NNRTIs
PI
Among  patients on ART, peroxide concentrations
(PC) were signiﬁcantly lower in NNRTI regimens
than in those receiving PIs ([IQR], 331.2 vs.
472.8 t∼mol/L; p = 0.003).
PC used as a marker of OS
was  associated with CVD
factors.  NNRTIs were
associated  with low PC vs.
patients  receiving PI
Reinsch et al., 201024 Cohort 698 HIV-positive patients PIs
NRTIs
NNRTIs
DD  was present in 336 (48%) of the total HIV
infected population. While not statistically
signiﬁcant, NRTI and PI use showed a trend
toward a greater prevalence in the DD group.
High  prevalence of DD in
HIV  patients was
demonstrated. Traditional
CVD  risk factors
contributed to the DD
Silva et al., 200925 Cohort 215 patients receiving
HAART  and 69
HAART-naive patients
G  A:
G B:
G C:
G D:
G E:
TC,  HDL, TG and glucose were higher in the
HAART group than in the non-HAART group
p < 0.001). According to the FRS, the CVD risk was
moderate  to high in 11% receiving HAART.
Although  the mean values
for  TC, HDL-c and TG were
higher  in the HAART group,
a  higher CVR was not
identiﬁed  in the former
Triant et al., 200726 Prospective cohort 3851 HIV and 1,044,589
non-HIV  patients
PIs
NRTIs
NNRTIs
AMI  was identiﬁed in 189 HIV and 26,142
non-HIV patients. AMI rates were increased in
HIV vs. non-HIV patients 11.13 vs. 6.98 (p < 0.001).
AMI  rates and CVR factors
were  increased in HIV
compared  with non-HIV
patients
Alvarez et al., 201027 Prospective cohort 4010 HIV patients The  overall prevalence of MS was 20.2%
(812/4010). The 10-year risk of developing CVD
was 10.4% (24.7). Patients with MS had higher
CVD risk 22.2% vs. 7.4%, respectively, p < 0.001.
MS in HIV-infected patients
receiving  ART is
comparable  to populations.
Patients  with MS had higher
estimated risk for CVD
b
 r
 a
 z
 j
 i
 n
 f
 e
 c
 t
 d
 i
 s
 .
 2
 0
 1
 3
;1
 7
(6
):691–700
 
695
Kwiatkowska et al.,
201128
Prospective cohort 72 HIV infected patients
and  27 healthy individuals
PIs,  NNRTIs,
NRTIs
HIV  infected patients show more advanced
subclinical atherosclerosis in the carotid arteries
(cIMT and plaques incidence). Patients treated
with ARV therapy for over 5 years have a higher
value of cIMT.
HIV shows signiﬁcant
progression of subclinical
atherosclerosis and
incidence  of atherosclerotic
plaques
D:A:D Study Group*,
200829
Prospective cohort 33,347 HIV-1-infected Associations between the rate of MI and
cumulative or recent use of AZT, d4T, or 3TC.
Recent use of ABC or ddI was associated with an
increased rate of MI relative rate 1.90 with ABC
and 1.49 with ddI [p = 0.003]).
There exists an increased
risk  of MI in patients
exposed  to ABC and ddI.
The  excess risk does not
seem  to be explained by
underlying  established CVD
risk  factors
SMART/INSIGHT and
DAD  Study, 200830
Prospective cohort 4544 HIV patients NRTIs
PIs
Use  of ABC was associated with an excess risk of
CVD compared with other NRTIs. Adjusted
hazard ratios for clinical MI (n = 19), major CVD
(MI,  stroke, surgery for CAD, and CVD death;
n = 70).
Current  use of ABC was
associated  with an excess
risk  of CVD compared with
other  NRTIs. The drug may
cause  vascular
inﬂammation, which may
precipitate  a CVD event
Obel et al., 200731 Prospective cohort 3953 HIV-infected patients
and  373,856 Control
subjects
PIs,
NNRTIs,
NRTIs
In  HAART period, the risk of ischemic heart
disease (IHD) increase was substantially higher
RR = 2.12. 1 year after receiving a diagnosis of HIV
infection, RR of IHD was 2.38.
Compared with the general
population,  HIV-infected
patients  receiving HAART
have  an increased risk of
IHD
Van Vonderen 200933 Case–control 55 HIV-patients ART, 22
HIV-patients  ART naive
23  HIV-patients with LD
52  controls – NA
NS  HIV infected patients had a 0.067 mm (10.8%)
greater CIMT than controls. Patients exposed to
ART had similar CIMT compared with ART-naive
patients but 25.9% lower DC and 21.7% lower CC
of the femoral artery.
HIV infection is
independently associated
with  C-IMT and generally
increased  arterial stiffness
Lang et al., 201034 Case–control 289 HIV-patients with
history  of MI
884  HIV-patients with no
history  of MI – 6 years
ABC,  AZT, d4T, 3TC, TDF Recent exposure to ABC was associated with an
increased risk of MI (OR, 2.01; 95% CI, 1.11–3.64)
Cumulative exposure to all PIs except SQV was
associated with an increased risk of MI.
Short-term/recent exposure
to  ABC was associated with
an  increased risk of MI
Wand et al., 200735 RTC 288  ddI/d4T with EFV
305  ddI/d4T with NFV
288  ddI/d4T with EFV+ NFV
–  3 years
ddI
d4T
EFV
NFV
MS  association with increased risk of CVD
HR = 2.56 and was associated with an increased
risk  of T2DM (ATP-III: HR = 4.34; p = 0.001).
Incident MS was associated with an increased
risk of both CVD (ATP-III: HR = 2.73; p = 0.036) and
T2DM (ATP-III: HR = 4.89; p < 0.0001).
Progression  to MS
696
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Table 2 (Continued)
Study Type of study Population-follow-up Drugs Results Outcomes
Van Vonderen et al.,
200936
RTC 19  HIV-patients with LPV/r
plus  ZDV/3TC
18  LPV/r plus NVP-
3  years
LPV/r
ZDV
3TC
NVP
CIMT increased by 0.061 mm (p < 0.001) in the
ZDV/3TC/LPV/r arm and by 0.044 mm (p = 0.012)
in the NVP/LPV/r arm. Femoral artery DC and CC
decreased in the ZDV/3TC/LPV/r arm and
femoral DC decreased in the NVP/LPV/r arm.
CIMT  and femoral artery
stiffness  increased after the
initiation of HAART
Martınez et al.,
201037
RTC 46 ABC/3TC
34 TDF/emtricitabine)
48 weeks
ABC
3TC
TDF
Emtricitabine
TC  increased signiﬁcantly in the ABC/3TC vs.
TFV/ETB group, found no signiﬁcant changes in
the biomarkers (p = 0.12 for all comparisons)
ABC/3TC increase TCl and
LDL
Did  not cause
inﬂammation,
endothelial dysfunction,
insulin  resistance
Murphy 201038 RTC 26  ATV/r
24 remained on PI regimen
24  weeks
ATV/r
Others
Changes in the ATV/r vs. continued PI group
were observed for TC (−25 vs. +1.5 mg/dl,
p = 0.009), TG (−58 vs. +3.5 mg/dl, p = 0.013), and
non  HDL-C (−27 vs. −0.5 mg/dL, p = 0.014).
ATV/r  improved lipid proﬁle
Did  not change endothelial
function,  inﬂammatory and
metabolic  markers
TC, total cholesterol; HDL-C and LDL-C, high and low-density lipoprotein cholesterol; TG, triglycerides; CVR, cardiovascular risk; MI, myocardial infarction; AMI, acute myocardial infarction; FRF,
Framingham risk score; CAD, coronary artery disorder; CIMT, carotid intima–media thickness; LD, lipodystrophy; MS, metabolic syndrome; 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; ddC,
zalcitabine; ddI, didanosine; EFV, efavirenz; IDV, indinavir; LPV, lopinavir/ritonavir; NFV, nelﬁnavir; NVP, nevirapine; SQV, saquinavir; TDF, tenofovir; ATV/r, atazanavir; ABC, Abacavir; ETB, emtricitabine;
OPG, osteoprotegerin; ADT, adiponectin.
G  A: (AZT) + (3TC) + EFV; G B: AZT + 3TC + LPV e AZT + 3TC + NFV; G C: AZT + 3TC + ATV/r; G D: (d4T) + 3TC + EFV; G E: d4T + 3TC + LPV e d4T +3 TC + NFV e d4T + ddI + LPV (RTI) – reverse transcriptase
inhibitors not speciﬁed (NS); not applicable (NA); relative risk (RR).
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The use of several antiretroviral agents favors the occur-
ence  of multiple metabolic and morphologic abnormalities,
ncluding dyslipidemia, insulin resistance, subcutaneous
at loss, visceral fat accumulation, and metabolic syn-
rome  (MS), which are associated with an increased
isk of premature atherosclerosis and MI.6,9,11,13,16,18,28
AART may  also indirectly or directly induce endothelial
ysfunction.19,24
HIV infection itself is an independent risk factor for
cute myocardial infarction (AMI), and increase arterial stiff-
ess.  Compared with the general population, HIV-infected
atients receiving HAART have an increased risk of AMI and
HD,18,26,31,33,36 and increase in thickness of the intima–media
omplex.28,33
Combination antiretroviral therapy is associated with
I,9,13,22,29 and longer exposure to HAART and/or PIs seem to
ncrease  the risk of MI.29,32 HIV-infected patients using PI had
lightly  higher CVD risk than those using NNRTI, and slightly
ncreased  risk for patients using abacavir (ABC) or didanosine
ddI).18,26 Recent ABC exposure was  signiﬁcantly associated
ith higher risk of atherosclerotic vascular events, CVD, and
n  increased risk of MI.21,30,34 There exists an increased risk
f  MI  in patients exposed to ABC and ddI within the preceding
ix  months.29
iscussion
ardiovascular complications of HIV disease are generally
ate  manifestations and may  be related to prolonged effects
f  immunosuppression and a complex interplay of mediator
ffects  from opportunistic infections, autoimmune response
o  viral infection, drug-related cardiotoxicity, nutritional deﬁ-
iencies, and prolonged immunosuppression.39
There are many  ways  to assess the risk of CVD and multiple
isk  factors can be examined, such as age, gender, body mass
ndex  (BMI), TC, LDL, TG, MS,  MS,  carotid intima–media thick-
ess  (CIMT). These traditional risk factors for CVD increase
isk  of cardiovascular events in both HIV-infected and unin-
ected  individuals.
For  HIV-infected patients the retroviral chronic infection
er  se, the use of HAART and/or at least some of the antiretro-
iral  drugs, and lipodistrophy can be considered additional
isk  factors. HIV infection plays a substantial role on blood
ipids  disorders and can induce endothelial cells injury which
eads  to a local inﬂammatory response that could promote
hrombosis, impair vessel responsiveness, and is an impor-
ant  factor for arterial plaque formation. HIV replication may
ctivate  endothelial surfaces directly or via up-regulation of
ro-inﬂammatory cytokines.
Some studies suggested that even though the overall car-
iovascular event rate is low, there is an excess risk of
ardiovascular events in HIV-infected persons compared to
on-HIV-infected individuals. Some evidence suggested that
IV-infected  individuals on HAART regimens are at increased
isk  of dyslipidemia, IHD, and MI,  particularly if the HAART
egimen contains a PI. While lipid-lowering drugs are a routine
trategy  for CVR reduction in the general population, HIV-
nfected  people are usually not on those drugs even when
linically  indicated.403;1 7(6):691–700  697
In this review we observed some different outcomes asso-
ciated  with different results. When the outcome was  MI and
the  use of ABC was  investigated, in three studies increased MI
incidence was  detected13,15,34 and in two studies there were no
signiﬁcant  differences.12,17 Recently, the U.S.  Food and Drug
Administration (FDA) conducted a meta-analysis in which
ABC  use was randomized as part of a combined antiretrovi-
ral  regimen and found no association between the use of ABC
and  MI.41
When the outcome was  the change in lipid proﬁle, two
studies  showed a reduction on TC, LDL, TG,10,38 and two
demonstrated an increase in blood lipids.11,37 Two studies
showed an increase in CIMT,10,33 and one demonstrated a
decrease  in CIMT.16
We  must be aware that the population studied in all of
the  reviewed studies are HIV-infected adult patients, but with
different  characteristics. The studied populations had differ-
ent  age ranges and gender; different stages of HIV infection
and  most of them were receiving different antiretroviral drugs
regimens,  which could have different effects not only in the
surrogate  markers of CD risk but mainly in the incidence of
CVD.
In  spite of individual studies suggesting that currently
available PIs could increase the CVR,18,26,29,32 the PI class
remained a very effective class of antiretroviral drugs for HIV
infection  therapy. Life expectancy for HIV-infected patients
has  improved by 20 years for those diagnosed at age 25–33
years,  and it is still improving. The HIV-infected population
is  becoming more  susceptible to all chronic diseases that are
observed  in non-HIV-infected patients with the presence of
additional  risk factors for CVD due to infection and the treat-
ment  itself.42
The clinical expression of cardiac involvement is vari-
able  and is affected by the stage of HIV disease, the degree
of  immunodeﬁciency, and the use of drugs to treat HIV
disease  or to treat or prevent opportunistic infections and
neoplasms.43 CVR must be considered in the overall care of
adults  with HIV infection. However, such risk should not inﬂu-
ence  the decision of when to initiate antiretroviral therapy,
and  the decision of which antiretroviral regimen to use should
be  made based on risk and beneﬁt analysis that includes the
clear  survival beneﬁt associated with maximal viral suppres-
sion.
HIV-infected patients confront an escalating epidemic of
CVD  that is comparable to that faced by the general popu-
lation  more  than half a century ago. Stratifying risk among
HIV-infected patients and devising cardiovascular preventive
strategies are priorities.44 The initial choice of ART regi-
men  and subsequent modiﬁcations also may  be considered
in  planning CVD prevention strategies, because the risks of
inadequately  treated HIV infection outweigh any increase in
CVD risk that may  be associated with ART, and with the
understanding that uncontrolled viral infection may itself
contribute  to CVD risk.45,46
CVD risk assessment and risk reduction are essential com-
ponents  of preventive medical care that are increasingly
important for patients with HIV. Physicians should system-
atically  assess their HIV-infected patients for CVR factors and
should  closely monitor patients receiving HAART, especially
those  with additional risk factors for CVD.47
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The role of the cardiologist in the evaluation and treatment
of  patients with HIV infection should therefore be expanded to
include patients who  are being evaluated for or who are receiv-
ing  HAART regimens, especially those with underlying CVR. It
may be important to consider traditional coronary risk proﬁles
and  to alter those that can be modiﬁed in the evaluation and
continued  therapy of patients with HAART.48 It is especially
important to develop simple and clear messages to educate
patients  about the importance of CVD prevention, the impor-
tance  of identifying and treating CVD risk factors or high CVD
risk,  and how smoking, adverse dietary habits, and physical
inactivity  increase CVD risk.49
Treatment options include the use of pharmacological
and non-pharmacological methods for managing dyslipide-
mia  and hyperglycemia, as well as considering lipid-neutral
HAART regimens for their patients, especially with the avail-
ability  of drugs in this class with less adverse impact on lipid
proﬁle.47 One potential strategy to manage dyslipidemia is
switching  the ARV drug that promotes the lipids increase.
However, it should be taken into consideration that it depends
on  the availability of remaining active drugs without impact
on  plasma lipids. In addition, switching requires a careful eval-
uation  of the risks of virological failure, especially for patients
with  previous failure to ARV regimens.
Dyslipidemic HIV/HAART patients have elevated levels of
lipoprotein-associated phospholipase A2 (Lp-PLA2). The main
physiological action of Lp-PLA2 is the hydrolysis of strongly
inﬂammatory phospholipids, such as platelet-activating fac-
tor which may  increase risk of CVD.50,51 Elevated plasma
Lp-PLA2 can be reduced by an intensive diet and exercise pro-
gram  in patients with HIV/HAART-associated dyslipidemia.51
Current guidelines recommend dietary intervention as ﬁrst
line  treatment for HIV dyslipidemia.52,53 Omega-3 supplemen-
tation has a triglyceride-lowering effect that may  impact on
cardiac  outcomes. Triglyceride levels represent an important
biomarker of CVD, because of their association with athero-
genic  remnant particles. The 33,308 HIV-infected included in
the study of Worm et al., with elevated triglyceride levels,
experienced 580 MIs  over 178,835 person-years. The risk of MI
increased by 67%, per doubling in triglyceride level.54
Recently, Stradling et al. conducted a Systematic Review
and  Meta-Analysis which provides evidence for a comparable
clinical  beneﬁt of dietary intervention or omega-3 supplemen-
tation  in reducing triglycerides.55 Diet supplementation with
ﬁsh  oil is prescribed when a suppression of lipid mobiliza-
tion  is desired. The use of antihyperlipidemic drugs should be
reserved for patients at high risk of cardiovascular events.56
Lifestyle changes (healthy diet, smoking cessation, and
daily  physical exercise) reduce the probability of a coro-
nary  event by up to 80% in the general population. Dietary,
pharmacological interventions and exercise are established
interventions to reduce metabolic changes and the relevant
risk.56
Exercise is consistently listed among the three most com-
mon  complementary and alternative therapies utilized by
HIV-infected  persons. A training program that involves con-
current  endurance and strength training must be prescribed.
Exercise aerobic should be performed at a moderate intensity:
from  11 to 14 on the Borg Rating of Perceived Exertion Scale,
or  50–85% of peak heart rate and resistance training should 1 3;1  7(6):691–700
focus on large muscle groups, with intensity of 60–80% of one
maximal  repetition and 8–12 repetitions.56,57
A signiﬁcant body of evidence suggests that there is a mea-
surable  increase in the risk of CVD in HIV-infected patients
with  varying effects from different antiretroviral drugs. In
spite  of studies, the impact of HIV and different HAART regi-
mens  on the risk of CVD in HIV-infected patients remains
somewhat obscure. Differences in study design, endpoints,
patient populations and limited follow-up in some studies
prevent  deﬁnitive comparisons.58
This review has several limitations, most of them due to
the  varying methodologies and study designs and inherent
limitations of observational studies, which makes it difﬁcult
to  control for population or selection bias. Furthermore, sub-
stantial  variations in study design complicate the analysis of
the  associations between HAART and CVD risk. Considering its
descriptive purpose and the ﬁndings of this review, it seems
reasonable to believe that both HIV infection and HAART have
potential  adverse impact on CVR factors and on the incidence
of  CVD.
Conclusion
There are many  studies addressing the relationship between
HAART  and CVD and it is an issue still under debate. However,
it  is clear that this combined antiretroviral therapy remarkably
decreased the overall mortality associated with HIV infection.
Our  review conﬁrms that HIV-infected patients present risk
of  CVD, and for this reason preventive strategies should be
focused  on smoking cessation, increase physical exercise, and
diet.
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